---
figid: PMC7859776__atm-09-01-38-f7
figtitle: An illustrative model to show the proposed mechanism of miR-126-3p promoting
  sorafenib resistance in HCC
organisms:
- Homo sapiens
- Mus musculus
- Danio rerio
- Equus caballus
- Hepatitis B virus
- Raphanus sativus
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Equus caballus
- Danio rerio
pmcid: PMC7859776
filename: atm-09-01-38-f7.jpg
figlink: pmc/articles/PMC7859776/figure/f7/
number: F7
caption: An illustrative model to show the proposed mechanism of miR-126-3p promoting
  sorafenib resistance in HCC. Sorafenib is a multikinase inhibitor which acts against
  several receptor tyrosine kinases, including PDGFR-β and VEGFR2, and then blocks
  the Raf/MEK/ERK signaling pathway. SPRED1 inhibits MEK/ERK activation by forming
  a complex with Raf. However, miR-126-3p can directly inhibit SPRED1 expression and
  then activate the ERK signaling pathway, thus impairing the anti-tumor effect of
  sorafenib against HCC. Taken together, inhibiting miR-126-3p could enhance sorafenib
  sensitivity against HCC through synergistically suppressing the Raf/MEK/ERK signaling
  pathway.
papertitle: miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma
  via downregulating SPRED1.
reftext: Wenliang Tan, et al. Ann Transl Med. 2021 Jan;9(1):38.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9462197
figid_alias: PMC7859776__F7
figtype: Figure
redirect_from: /figures/PMC7859776__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7859776__atm-09-01-38-f7.html
  '@type': Dataset
  description: An illustrative model to show the proposed mechanism of miR-126-3p
    promoting sorafenib resistance in HCC. Sorafenib is a multikinase inhibitor which
    acts against several receptor tyrosine kinases, including PDGFR-β and VEGFR2,
    and then blocks the Raf/MEK/ERK signaling pathway. SPRED1 inhibits MEK/ERK activation
    by forming a complex with Raf. However, miR-126-3p can directly inhibit SPRED1
    expression and then activate the ERK signaling pathway, thus impairing the anti-tumor
    effect of sorafenib against HCC. Taken together, inhibiting miR-126-3p could enhance
    sorafenib sensitivity against HCC through synergistically suppressing the Raf/MEK/ERK
    signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pdgfrb
  - Kdr
  - Mir126a
  - ras
  - Hras
  - Kras
  - Rem1
  - Spred1
  - Zhx2
  - Mapk3
  - Mapk1
  - PDGFRB
  - KDR
  - MIR126
  - KRAS
  - HRAS
  - NRAS
  - SPRED1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAPK3
  - MAPK1
  - HCC
  - HYCC1
  - pdgfrb
  - kdrl
  - mir126a
  - rab1ab
  - spred1
  - mapk3
  - hccsa.2
  - sorafenib
---
